Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
- PMID: 17082201
- DOI: 10.1093/jac/dkl441
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
Abstract
Objectives: Tigecycline has shown in vitro activity against Acinetobacter baumannii. Yet, published clinical experience with tigecycline use outside clinical trials is lacking. We describe, for the first time, bloodstream infection caused by tigecycline-non-susceptible A. baumannii occurring in patients receiving tigecycline for other indications. The possible mechanisms of resistance and pharmacokinetic limitations of the drug are addressed.
Methods: The clinical records of involved patients were systematically reviewed. Tigecycline susceptibility testing was initially performed using the Etest method and confirmed by agar dilution. Involved isolates underwent PFGE and exposure to phenyl-arginine-beta-naphthylamide (PAbetaN), an efflux pump inhibitor.
Results: Two patients developed A. baumannii bloodstream infection while receiving tigecycline. Tigecycline was administered for other indications for 9 and 16 days, respectively, before the onset of A. baumannii infection. Patient 1 died of overwhelming A. baumannii infection and Patient 2 recovered after a change in antibiotic therapy. The MICs of tigecycline were 4 and 16 mg/L, respectively. Both isolates had a multidrug-resistant phenotype and were genotypically unrelated. After exposure to PAbetaN, the MICs reduced to 1 and 4 mg/L, respectively.
Conclusions: To our knowledge, this is the first clinical description of bloodstream infection caused by tigecycline-non-susceptible A. baumannii. Such resistance appears to be at least partly attributable to an efflux pump mechanism. Given the reported low serum tigecycline levels, we urge caution when using this drug for treatment of A. baumannii bloodstream infection.
Similar articles
-
High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.J Antimicrob Chemother. 2007 Apr;59(4):772-4. doi: 10.1093/jac/dkm018. Epub 2007 Mar 12. J Antimicrob Chemother. 2007. PMID: 17353223
-
Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.Pharmacotherapy. 2007 Jul;27(7):980-7. doi: 10.1592/phco.27.7.980. Pharmacotherapy. 2007. PMID: 17594203
-
In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.Int J Antimicrob Agents. 2008 Nov;32 Suppl 3:S188-91. doi: 10.1016/S0924-8579(08)70026-8. Int J Antimicrob Agents. 2008. PMID: 19013353
-
Treatment of multiresistant Acinetobacter baumannii infections.Curr Opin Investig Drugs. 2009 Feb;10(2):150-6. Curr Opin Investig Drugs. 2009. PMID: 19197792 Review.
-
Optimizing therapy for Acinetobacter baumannii.Semin Respir Crit Care Med. 2007 Dec;28(6):662-71. doi: 10.1055/s-2007-996413. Semin Respir Crit Care Med. 2007. PMID: 18095230 Review.
Cited by
-
Emerging threat of multidrug resistant bugs--Acinetobacter calcoaceticus baumannii complex and methicillin resistant Staphylococcus aureus.BMC Res Notes. 2013 Mar 15;6:98. doi: 10.1186/1756-0500-6-98. BMC Res Notes. 2013. PMID: 23497675 Free PMC article.
-
Essential biological processes of an emerging pathogen: DNA replication, transcription, and cell division in Acinetobacter spp.Microbiol Mol Biol Rev. 2010 Jun;74(2):273-97. doi: 10.1128/MMBR.00048-09. Microbiol Mol Biol Rev. 2010. PMID: 20508250 Free PMC article. Review.
-
Genetic Determinants of Acinetobacter baumannii Serum-Associated Adaptive Efflux-Mediated Antibiotic Resistance.Antibiotics (Basel). 2023 Jul 11;12(7):1173. doi: 10.3390/antibiotics12071173. Antibiotics (Basel). 2023. PMID: 37508269 Free PMC article.
-
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.J Antimicrob Chemother. 2008 Jul;62(1):45-55. doi: 10.1093/jac/dkn165. Epub 2008 Apr 24. J Antimicrob Chemother. 2008. PMID: 18436554 Free PMC article. Review.
-
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Haematologica. 2013 Dec;98(12):1836-47. doi: 10.3324/haematol.2013.091330. Haematologica. 2013. PMID: 24323984 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical